Catalyst Health Economics Consultants

Utility values for chronic myelogenous leukaemia chronic phase health states from the general public in the United Kingdom.

Author: JF Guest, N Naik, E Sladkevicius, J Coombs, EJ Gray.
Source: Leukemia & Lymphoma 2011; 53(5):928-933.


This study estimated time trade-off preference values associated with the four chronic myelogenous leukaemia (CML) chronic phase-related health states (i.e. untreated, haematologic response, cytogenetic response and molecular response) among members of the general public in the UK (n = 241). All four health states were associated with decreases in preference values from full health. The molecular response to treatment was the most preferred health state (mean utility of 0.94). The second-most preferred health state was cytogenetic response followed by haematologic response (mean utilities were 0.89 and 0.80 respectively). The least preferred health state was untreated chronic phase CML (mean utility of 0.72). The utility values for each state was significantly different from one another (p <0.001). This study demonstrated and quantified the impact that more robust treatment responses have on the health-related quality of life of patients with chronic phase CML.

<<< Go Back

Catalyst Health Economics Consultants Ltd
© 1991 - 2019